Immune Minimization Strategies in Renal Transplantation

References

• Abbas AK. (2011). Cellular and Molecular Immunology. Philadelphia: Saunders/Elsevier
   Google Scholar
• Abramowicz D, Del Carmen Rial M, Vitko S, et al. (2005). Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol, 16, 2234–40
   PubMed Web of Science ®Google Scholar
• Ahsan N, Hricik D, Matas A, et al. (1999). Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil—A prospective randomized study. Steroid Withdrawal Study Group. Transplantation, 68, 1865–74
   PubMed Web of Science ®Google Scholar
• Almawi WY, Melemedjian OK, Rieder MJ. (1999). An alternate mechanism of glucocorticoid anti-proliferative effect: Promotion of a Th2 cytokine-secreting profile. Clin Transplant, 13, 365–74
   PubMed Web of Science ®Google Scholar
• Cibrik D, Silva HT, Jr., Vathsala A, et al. (2013). Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation, 95, 933–42
   PubMed Web of Science ®Google Scholar
• Citterio F. (2001). Steroid side effects and their impact on transplantation outcome. Transplantation, 72, S75–80
   Web of Science ®Google Scholar
• DeVos JM, Gaber AO, Knight RJ, et al. (2012). Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int, 82, 598–604
   PubMed Web of Science ®Google Scholar
• Dudley C, Pohanka E, Riad H, et al. (2005). Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: The “creeping creatinine” study. Transplantation, 79, 466–75
   PubMed Web of Science ®Google Scholar
• Ekberg H, Grinyo J, Nashan B, et al. (2007a). Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant, 7, 560–70
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al. (2007b). Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med, 357, 2562–75
   PubMed Web of Science ®Google Scholar
• Everly MJ, Everly JJ, Arend LJ, et al. (2009). Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant, 9, 1063–71
   PubMed Web of Science ®Google Scholar
• Frimat L, Cassuto-Viguier E, Charpentier B, et al. (2006). Impact of cyclosporine reduction with MMF: A randomized trial in chronic allograft dysfunction. The ‘reference' study. Am J Transplant, 6, 2725–34
   PubMed Web of Science ®Google Scholar
• Gaston RS, Cecka JM, Kasiske BL, et al. (2010). Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation, 90, 68–74
   PubMed Web of Science ®Google Scholar
• Humar A, Gillingham K, Kandaswamy R, et al. (2007). Steroid avoidance regimens: A comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode. Am J Transplant, 7, 1948–53
   PubMed Web of Science ®Google Scholar
• Jardine AG. (2005). Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int, 18, 379–84
   PubMed Web of Science ®Google Scholar
• Johnson RW, Kreis H, Oberbauer R, et al. (2001). Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation, 72, 777–86
   PubMed Web of Science ®Google Scholar
• Laftavi MR, Stephan R, Stefanick B, et al. (2005). Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery, 137, 364–71
   PubMed Web of Science ®Google Scholar
• Larson TS, Dean PG, Stegall MD, et al. (2006). Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant, 6, 514–22
   PubMed Web of Science ®Google Scholar
• Matas AJ. (2009). Minimization of steroids in kidney transplantation. Transpl Int, 22, 38–48
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. (2004). Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant, 4, 378–83
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Borrows RJ, Fung CL, et al. (2004). Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation, 78, 557–65
   PubMed Web of Science ®Google Scholar
• Oberbauer R, Segoloni G, Campistol JM, et al. (2005). Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int, 18, 22–8
   PubMed Web of Science ®Google Scholar
• Ojo AO, Held PJ, Port FK, et al. (2003). Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med, 349, 931–40
   PubMed Web of Science ®Google Scholar
• Pascual J, Royuela A, Galeano C, et al. (2012). Very early steroid withdrawal or complete avoidance for kidney transplant recipients: A systematic review. Nephrol Dial Transplant, 27, 825–32
   PubMed Web of Science ®Google Scholar
• Prasad GV, Nash MM, McFarlane PA, Zaltzman JS. (2003). Renal transplant recipient attitudes toward steroid use and steroid withdrawal. Clin Transplant, 17, 135–9
   PubMed Web of Science ®Google Scholar
• Rostaing L, Vincenti F, Grinyo J, et al. (2013). Long-term belatacept exposure maintains efficacy and safety at 5 years: Results from the long-term extension of the BENEFIT study. Am J Transplant, 13, 2875–83
   PubMed Web of Science ®Google Scholar
• Rostaing L, Cantarovich D, Mourad G, et al. (2005). Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation, 79, 807–14
   PubMed Web of Science ®Google Scholar
• Schena FP, Pascoe MD, Alberu J, et al. (2009). Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation, 87, 233–42
   PubMed Web of Science ®Google Scholar
• Sellares J, de Freitas DG, Mengel M, et al. (2012). Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant, 12, 388–99
   PubMed Web of Science ®Google Scholar
• Sinclair NR. (1992). Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ, 147, 645–57
   PubMed Web of Science ®Google Scholar
• Snanoudj R, Royal V, Elie C, et al. (2011). Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant, 11, 2635–46
   PubMed Web of Science ®Google Scholar
• Vanrenterghem Y, Lebranchu Y, Hene R, et al. (2000). Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation, 70, 1352–9
   PubMed Web of Science ®Google Scholar
• Veenstra DL, Best JH, Hornberger J, et al. (1999). Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis, 33, 829–39
   PubMed Web of Science ®Google Scholar
• Vincenti F, Schena FP, Paraskevas S, et al. (2008). A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant, 8, 307–16
   PubMed Web of Science ®Google Scholar
• Weir MR, Mulgaonkar S, Chan L, et al. (2011). Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial. Kidney Int, 79, 897–907
   PubMed Web of Science ®Google Scholar
• Wiebe C, Gibson IW, Blydt-Hansen TD, et al. (2012). Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant, 12, 1157–67
   PubMed Web of Science ®Google Scholar
• Wolfe RA, Ashby VB, Milford EL, et al. (1999). Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med, 341, 1725–30
   PubMed Web of Science ®Google Scholar
• Woodle ES, First MR, Pirsch J, et al. (2008). A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg, 248, 564–77
   PubMed Web of Science ®Google Scholar